euglena Co., Ltd. (2931) AI Stock Analysis

• Market Cap: ¥52.78B
• Dividend Yield: N/A
• Average Volume (3M): 958.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.69
• Revenue Growth: 3.68%
• EPS Growth: N/A
• Country: JP
• Employees: 897
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): -3.11
• Shares Outstanding: 139,273,060
• 10 Day Avg. Volume: 1,429,850
• 30 Day Avg. Volume: 958,053
• PEG Ratio: -3.10
• Price to Book (P/B): 1.76
• Price to Sales (P/S): 1.08
• P/FCF Ratio: 10.97
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 4
• Revenue Forecast (FY): ¥48.90B

• Rating: 48 Neutral
• Price Target: ¥392.00 ▼(-3.69% Downside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is held back primarily by continued net losses (negative P/E) and a weak technical trend with the stock trading below major moving averages. These risks are partially offset by improving fundamentals, including strong revenue growth, a shift to positive operating profit, and materially better operating and free cash flow in 2024–2025.

Positive Factors

Multi-year revenue growth

Sustained revenue expansion over multiple years demonstrates durable commercial traction and scale in both consumer and B2B channels. Higher top-line provides capacity to absorb fixed costs, negotiate better supplier terms, fund R&D and marketing, and supports a continued investment-led growth strategy.

Negative Factors

Ongoing net losses / negative ROE

Persisting net losses and negative ROE constrain retained earnings and shareholder returns despite operational gains. Until net profitability is consistently achieved, the company faces limits on dividend capacity, heightened scrutiny on capital allocation, and potential dilution risks if external capital is needed.

euglena Co., Ltd. Business Overview & Revenue Model

Company Description

Euglena Co., Ltd. engages in the research, development, production, and sale of microalgae. It operates through Healthcare Business and Energy/Environment Business segments. The company also manufactures and sells foods and cosmetics using euglena...

Read more

Euglena Co., Ltd. engages in the research, development, production, and sale of microalgae. It operates through Healthcare Business and Energy/Environment Business segments. The company also manufactures and sells foods and cosmetics using euglena...

How the Company Makes Money

Euglena Co., Ltd. generates revenue through multiple streams, primarily by selling dietary supplements and functional foods that incorporate Euglena as a key ingredient. The company has developed a range of products targeting health-conscious cons...

Read more

Euglena Co., Ltd. generates revenue through multiple streams, primarily by selling dietary supplements and functional foods that incorporate Euglena as a key ingredient. The company has developed a range of products targeting health-conscious cons...

euglena Co., Ltd. Financial Statement Overview

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	48.52B	50.37B	47.62B	46.48B	44.39B	27.54B
Gross Profit	33.98B	35.03B	30.00B	29.81B	29.05B	16.22B
EBITDA	5.23B	6.47B	3.90B	1.51B	-359.00M	-3.50B
Net Income	-942.00M	-805.00M	-650.00M	-2.65B	-2.67B	-4.03B
Balance Sheet
Total Assets	69.09B	72.33B	73.26B	59.62B	57.27B	61.01B
Cash, Cash Equivalents and Short-Term Investments	18.54B	21.16B	20.63B	15.79B	9.95B	10.19B
Total Debt	22.66B	27.68B	25.92B	25.07B	22.22B	24.91B
Total Liabilities	37.38B	43.80B	41.14B	39.40B	37.92B	40.42B
Stockholders Equity	30.59B	30.96B	31.70B	20.21B	19.35B	20.58B
Cash Flow
Free Cash Flow	2.41B	4.98B	2.23B	345.00M	595.00M	1.18B
Operating Cash Flow	2.66B	5.19B	2.65B	658.00M	924.00M	1.38B
Investing Cash Flow	-7.63B	-585.00M	-7.99B	-646.00M	1.23B	-10.34B
Financing Cash Flow	-992.00M	-2.43B	-485.00M	5.83B	-2.99B	12.06B

euglena Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 407.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2931, the sentiment is Neutral. The current price of 407 is above the 20-day moving average (MA) of 373.05, above the 50-day MA of 391.80, and below the 200-day MA of 422.87, indicating a neutral trend. The MACD of -4.48 indicates Negative momentum. The RSI at 49.75 is Neutral, neither overbought nor oversold. The STOCH value of 52.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:2931.

euglena Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4527	71 Outperform	¥559.97B	13.97	12.66%	1.53%	18.35%	31.87%
4452	70 Outperform	¥2.78T	24.05	11.50%	2.41%	4.62%	47.68%
4922	69 Neutral	¥343.10B	19.79	2.72%	2.61%	1.37%	-5.60%
4967	65 Neutral	¥434.30B	110.37	5.37%	1.95%	-3.33%	13.76%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
4911	56 Neutral	¥1.28T	-22.37	―	2.11%	-1.20%	-2896.72%
2931	48 Neutral	¥52.78B	-67.83	―	―	3.68%	―

euglena Co., Ltd. Corporate Events